leisure time -WSS

leisure time

author：leisure time 2025-08-27 16:48:08 - browse：4

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA drug safety: Singulair case shows systemic surveillance flaws

focus

WSS

Neuroscience’s long legacy of racism

Leading voice in opioid treatment defends methadone clinic system

Woodcock on FDA’s accelerated approval and her next chapter

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Congressmen charge Covid hearing ‘could have been an email’

Neuroscience’s long legacy of racism

Wikipedia

leisure time

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

New air purifier tech could be key to improving indoor air quality

Gene editing the human germline: What are the risks?

United colonoscopy coverage change 'may cost lives,' doctors say

Cognito secures funding to test medical device for Alzheimer's

Moonlake's readout produced a cash windfall. Risks remain

Apple Vision Pro: A first look at health apps on the new VR headset

As demand for Covid shots wanes, Moderna seeks its next success

Orchard's therapy for neuron disease in children wins FDA approval

Medical records are filled with copy

The lessons of Aduhelm, an Alzheimer's drug that was not to be

focus

Colonoscopy prep: Liquid

Readout Newsletter: Bluebird, CVS, Contineum

Colonoscopy prep: Liquid

Orchard's therapy for neuron disease in children wins FDA approval

Commercial surrogacy can be ethical, despite pope’s claims

Biden administration opens offers in Medicare drug price negotiations

knowledge

focus

focus

knowledge